Metraipolis › archive › dc_a48c558f61eb

Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome — Europe PMC PMID:42183294

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42183294
DOI
10.3389/fimmu.2026.1739437
License (as archived)
solo-consultazione
Archived
2026-10-09T23:19:46.072Z
SHA-256 of the archived text
01556c0678a639bea418c15cc06efd283355d43cfabb08bdaa8d0cbe4f440b53
Stable URL of this page
https://metraipolis.com/documento/dc_a48c558f61eb

How to cite

Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome — Europe PMC PMID:42183294 — Europe PMC (en), https://europepmc.org/article/MED/42183294 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a48c558f61eb (Metraipolis archive dc_a48c558f61eb, sha256 01556c0678a639bea418c15cc06efd283355d43cfabb08bdaa8d0cbe4f440b53)
BibTeX
@misc{dca48c558f61eb,
  title = {Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome — Europe PMC PMID:42183294},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42183294},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a48c558f61eb; sha256 01556c0678a639bea418c15cc06efd283355d43cfabb08bdaa8d0cbe4f440b53},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42183294. Agents can read the archived copy with the MCP tool read_document.